pyridostigmine bromide has been researched along with Autoimmune Experimental Myasthenia Gravis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilyin, VI; Kharlamova, AD; Lenina, OA; Nikolsky, EE; Nurtdinov, AR; Petrov, KA; Sitdykova, ME; Zueva, IV | 1 |
| Ghazanfari, N; Morsch, M; Phillips, WD; Reddel, SW; Toyka, KV | 1 |
2 other study(ies) available for pyridostigmine bromide and Autoimmune Experimental Myasthenia Gravis
| Article | Year |
|---|---|
Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment.
Topics: Animals; Cholinesterase Inhibitors; Humans; Intestines; Muscle Contraction; Muscle, Smooth; Myasthenia Gravis, Autoimmune, Experimental; Pyridostigmine Bromide; Quaternary Ammonium Compounds; Rats; Uracil; Urinary Bladder | 2018 |
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Cholinesterase Inhibitors; Evoked Potentials; Female; Humans; Immunoglobulin G; Mice; Mice, Inbred C57BL; Muscle Weakness; Muscle, Skeletal; Myasthenia Gravis, Autoimmune, Experimental; Neuromuscular Junction; Pyridostigmine Bromide; Receptor Protein-Tyrosine Kinases; Receptors, Cholinergic | 2013 |